Professor Charles Coombes, Professor of Medical Oncology, Imperial College London. He is also Hon Consultant Medical Oncologist, Imperial College Healthcare Trust.
From October 2010 Professor Coombes is Director of The Imperial CRUK Cancer Centre. He is also Chair of The Imperial Cancer Research (UK) Centre Steering Committee and Theme leader for Cancer, Imperial College London.
He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs.
In his capacity as Head of Division of Cancer until 30 September 2012, he was responsible for the running of the division, as well as the recruitment and retention of staff. He is personally responsible for running the section of Cancer Cell Biology and has three CRUK Programme Grants and many other project and smaller grants. This department currently has more than 280 scientific staff. The department has doubled in size over the past three years and now has and I4 Professors and twenty sections.
His laboratory is focusing on elucidating molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways. He works with scientists engaged in molecular target identification and chemists whose remit is to target specific signalling abnormalities to develop novel therapies for breast cancer. He also runs a translational laboratory which focuses on detection of micrometastatic disease and application to the treatment of breast cancer. He is Chairman of the International Collaborative Cancer Group. This is a multinational trial centre which is based within Imperial College focussing on phase II and phase III studies in breast cancer.
Many lectures each year: In the past two years I have been invited to give lectures in Australia, Taiwan, Japan, China, India, Brazil, Mexico, The USA, Holland, Belgium, Germany, Spain, Italy, Sweden, and Finland.
et al., 2017, Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer, Breast Cancer Research and Treatment, Vol:163, ISSN:0167-6806, Pages:461-474
et al., 2017, NY-ESO-1 expression in DCIS: A new predictor of good prognosis., Oncoscience, Vol:4, ISSN:2331-4737, Pages:33-40
et al., 2017, Stratified, precision or personalised medicine? Cancer services in the "real world' of a London hospital, Sociology of Health & Illness, Vol:39, ISSN:0141-9889, Pages:143-158
et al., 2017, Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer, Oncogene, Vol:36, ISSN:0950-9232, Pages:2286-2296
et al., 2017, Inhibitor Selectivity for Cyclin-Dependent Kinase7: AStructural, Thermodynamic, and Modelling Study, Chemmedchem, Vol:12, ISSN:1860-7179, Pages:372-380